about
In vitro study on the schedule-dependency of the interaction between pemetrexed, gemcitabine and irradiation in non-small cell lung cancer and head and neck cancer cellsTowards Prognostic Profiling of Non-Small Cell Lung Cancer: New Perspectives on the Relevance of Polo-Like Kinase 1 Expression, the TP53 Mutation Status and HypoxiaThe radiosensitising effect of gemcitabine and its main metabolite dFdU under low oxygen conditions is in vitro not dependent on functional HIF-1 protein.Comparative analysis of dynamic cell viability, migration and invasion assessments by novel real-time technology and classic endpoint assays.Primary skeletal muscle myoblasts from chronic heart failure patients exhibit loss of anti-inflammatory and proliferative activity.Long-Term Depletion of Conventional Dendritic Cells Cannot Be Maintained in an Atherosclerotic Zbtb46-DTR Mouse ModelReview: implications of in vitro research on the effect of radiotherapy and chemotherapy under hypoxic conditions.Pharmacological levels of Withaferin A (Withania somnifera) trigger clinically relevant anticancer effects specific to triple negative breast cancer cellsRole of cell cycle perturbations in the combination therapy of chemotherapeutic agents and radiation.Anti-epidermal growth factor receptor therapy in head and neck squamous cell carcinoma: focus on potential molecular mechanisms of drug resistanceExpression analysis on archival material revisited: isolation and quantification of RNA extracted from FFPE samples.Expression analysis on archival material: comparison of 5 commercially available RNA isolation kits for FFPE material.MDM2 SNP309 and SNP285 Act as Negative Prognostic Markers for Non-small Cell Lung Cancer Adenocarcinoma Patients.APR-246 (PRIMA-1(MET)) strongly synergizes with AZD2281 (olaparib) induced PARP inhibition to induce apoptosis in non-small cell lung cancer cell lines.In vitro and in vivo investigations on the antitumour activity of Chelidonium majus.Spotlight on Volasertib: Preclinical and Clinical Evaluation of a Promising Plk1 Inhibitor.The MDM2-inhibitor Nutlin-3 synergizes with cisplatin to induce p53 dependent tumor cell apoptosis in non-small cell lung cancerOvercoming cetuximab resistance in HNSCC: the role of AURKB and DUSP proteins.Retention of the in vitro radiosensitizing potential of gemcitabine under anoxic conditions, in p53 wild-type and p53-deficient non-small-cell lung carcinoma cells.The role of apoptotic cell death in the radiosensitising effect of gemcitabine.Chemoradiation interactions under reduced oxygen conditions: Cellular characteristics of an in vitro model.Reducing Compounds Equivocally Influence Oxidation during Digestion of a High-Fat Beef Product, which Promotes Cytotoxicity in Colorectal Carcinoma Cell Lines.Dual Targeting of Epidermal Growth Factor Receptor and HER3 by MEHD7945A as Monotherapy or in Combination with Cisplatin Partially Overcomes Cetuximab Resistance in Head and Neck Squamous Cell Carcinoma Cell Lines.Poly(I:C) primes primary human glioblastoma cells for an immune response invigorated by PD-L1 blockade.Preclinical and clinical studies on afatinib in monotherapy and in combination regimens: Potential impact in colorectal cancer.Deep sequencing of the TP53 gene reveals a potential risk allele for non-small cell lung cancer and supports the negative prognostic value of TP53 variants.Baseline [(18)F]FMISO μPET as a Predictive Biomarker for Response to HIF-1α Inhibition Combined with 5-FU Chemotherapy in a Human Colorectal Cancer Xenograft Model.Simultaneous targeting of EGFR, HER2, and HER4 by afatinib overcomes intrinsic and acquired cetuximab resistance in head and neck squamous cell carcinoma cell lines.Efficacy Screening of Gloriosa Superba Extracts in a Murine Pancreatic Cancer Model Using (18)F-FDG PET/CT for Monitoring Treatment Response.Hypoxia-Induced Cisplatin Resistance in Non-Small Cell Lung Cancer Cells Is Mediated by HIF-1α and Mutant p53 and Can Be Overcome by Induction of Oxidative Stress.Counting clonogenic assays from normoxic and anoxic irradiation experiments manually or by using densitometric softwareOvercoming Intrinsic and Acquired Cetuximab Resistance in RAS Wild-Type Colorectal Cancer: An In Vitro Study on the Expression of HER Receptors and the Potential of AfatinibRANK-RANKL Signaling in Cancer of the Uterine Cervix: A Review.Monitoring EGFR TKI resistance in real time using ddPCR-based liquid biopsy: a case reportRANK/RANKL signaling inhibition may improve the effectiveness of checkpoint blockade in cancer treatmentRadiosensitization of Non-Small Cell Lung Cancer Cells by the Plk1 Inhibitor Volasertib Is Dependent on the p53 StatusThe Benefit of Reactivating p53 under MAPK Inhibition on the Efficacy of Radiotherapy in Melanoma
P50
Q33665367-498AC240-7363-445F-9F44-972CCFEC89F0Q33820876-8CC2C7E6-5B21-477C-B80F-BEDB2DA6EC1EQ34123758-0B102F29-5F91-45AC-A124-B93109A9C740Q34456201-E53F2CB1-AABB-433A-BE1E-A5931106140CQ36031047-8F3F2AAB-4EE1-4A3A-94BF-BCF0DECEF914Q36242772-EF95A131-4E79-43A9-8CC1-58FB16186AF3Q36865505-A8C39565-4596-4469-912F-227DB9DE4B6DQ37548974-3C4C24CB-E0E2-4BA4-8C07-AC5DD200C9E7Q37797479-ABCC3E29-6F99-4467-ABBA-9E750E005D2EQ38118934-0C2F7E35-1FD0-4AB2-80A2-6F151E4079C7Q38398287-C9E73155-E737-4190-B7CF-34E9530DA690Q38407039-19A1F8B9-AC14-41E7-BCA9-84E904CFA602Q38619011-93612E55-56D9-4573-A9DF-DFE775309C02Q38786490-08A71A19-D177-4BE1-8366-82507465A6C3Q38815237-30BDE05E-ED6C-41EE-97C1-4F63497C6BC5Q38824242-419FD215-E5FF-4564-BF99-8155F38C69FFQ38858580-160B6FE0-E928-4BC9-AFB9-F836D2B5FECEQ38959451-24639E5E-35EF-4581-B4B6-BEEBF5808876Q39580891-25BF9478-F4F8-4345-9AA7-C4B80C584B4DQ39813658-E4D6BB38-FCE9-4E6E-8CC7-1BDB0F3D0696Q39835903-03281469-FC84-41E2-B6AD-D55731A00564Q49076492-52082FA1-0F9A-4EA2-8CE5-F16646ED68FDQ50093426-F3A22005-034F-439F-82A7-8CB92BBE9ACDQ50423292-3FD76D11-FDF3-4C03-AAAB-7FE8D730DA50Q50789654-D5386524-A8AB-4D3B-B601-AB09EB05069CQ51121284-2C3F716E-8C27-4F34-A0D6-9CB7FA816D14Q51559766-AAB02884-FF28-4A84-9F27-DD6B043CE25EQ52617485-6011E2EA-FD4C-4EC2-8498-95B7027E33B5Q52983546-D7CDCCFA-1F90-4A85-BD8F-7F215354120DQ53691994-237E319C-D576-47DB-AB6B-155C4B7585ACQ60531416-1E559424-7C7E-40A3-AC30-810764FC9B2AQ61816598-FB01EC97-0AFA-4D8F-8EBE-45C817C89D4BQ64939796-29E11E98-417E-4220-BB27-96B91A200E1CQ88938150-A6B8D675-B5F1-4FEC-B036-8F36748A80EFQ91128995-65C1B679-2A9B-4573-9F68-26CB0528D1BDQ91643126-02FAB077-15E7-4BD1-8BD6-BDF3F12031FCQ92372745-CA1C7782-7512-42E5-91BA-9AA79F5B90B6
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
An Wouters
@ast
An Wouters
@en
An Wouters
@es
An Wouters
@nl
type
label
An Wouters
@ast
An Wouters
@en
An Wouters
@es
An Wouters
@nl
prefLabel
An Wouters
@ast
An Wouters
@en
An Wouters
@es
An Wouters
@nl
P1053
B-5384-2017
P106
P21
P31
P3829
P496
0000-0001-7771-1239
P569
2000-01-01T00:00:00Z